Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant durvalumab versus placebo after complete resection of non-small cell lung cancer
NL-OMON54539Phase 3Recruiting
- Sponsor
- NVALT
- Start
- Apr 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoint: Disease-free survival in PD-L1-positive patients. Started Apr 2017; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON54539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54539.